Subscribe
scientist-istock-505918900
gevende / iStockphoto.com
6 February 2019Americas

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion ($3.3 billion) immunotherapy deal with Germany-based Merck KGaA.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers